Results 51 to 60 of about 801 (115)

The place of atypical antipsychotics in the treatment- resistant depressions

Psychiatry and Clinical Psychopharmacology, 2021
A third of major depressive disorder patients do not respond to treatment and are declared treatment resistant despite being prescribed appropriate antidepressants at adequate dose for adequate duration.
Mesut Çetin
doaj  

Clozapine-Induced Phototoxicity: An Unusual Side Effect of Atypical Antipsychotics

Case Reports in Dermatological Medicine, 2018
Introduction. Clozapine is a second-generation antipsychotic used for treatment-refractory schizophrenia. Photosensitivity is a major concern when prescribing typical antipsychotics, while atypical antipsychotics are thought to be less photosensitive ...
S. Al-Aojan, A. Al-Khalifah
doaj   +1 more source

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

Neuropsychiatric Disease and Treatment, 2021
Benjamin Kearns, Katy Cooper, Anna Cantrell, Chloe Thomas School of Health and Related Research, The University of Sheffield, Sheffield, UKCorrespondence: Benjamin Kearns Email b.kearns@sheffield.ac.ukPurpose: Cardiovascular and metabolic adverse events ...
Kearns B, Cooper K, Cantrell A, Thomas C
doaj  

Second-Generation Antipsychotics and Suicide

The Journal of Clinical Psychiatry, 2021
openaire   +3 more sources

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia

Neuropsychiatric Disease and Treatment, 2013
Kenji Washida,1,2 Toshihiko Takeda,2 Toshiaki Habara,2 Soichiro Sato,2 Takuro Oka,2 Masuo Tanaka,2 Yusaku Yoshimura,2 Shozo Aoki11Department of Psychiatry, Kawasaki Medical Graduate School, Kurashiki, Japan; 2Zikei Hospital, Okayama, JapanAim: The aim of
Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, Yoshimura Y, Aoki S   +7 more
doaj  

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

Neuropsychiatric Disease and Treatment, 2019
Kristen Ward,1 Leslie Citrome2 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; 2Department of Psychiatry and Behavioral Science, New York Medical College, Valhalla, NY, USA Abstract: The purpose of this
Ward K, Citrome L
doaj  

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East

Neuropsychiatric Disease and Treatment, 2015
Sulaiman Alkhadhari,1 Nasser Al Zain,2 Tarek Darwish,3 Suhail Khan,4 Tarek Okasha,5 Hisham Ramy,5 Talaat Matar Tadros6 1Kuwait Center for Mental Health, Safat, Kuwait; 2Al Amal Complex for Mental Health Hospital, Dammam, Saudi Arabia; 3Behavioural ...
Alkhadhari S, Al Zain N, Darwish T, Khan S, Okasha T, Ramy H, Tadros TM   +6 more
doaj  

Metabolic monitoring of psychiatric patients on second-generation antipsychotics

Annals of General Psychiatry, 2008
Bobotas Konstantinos, Tsiftsoglou Keranio, Georgiadou Olga, Markopoulou Maria   +3 more
doaj   +1 more source

Sex differences in side effects of second-generation antipsychotics

Annals of General Psychiatry, 2008
Paterakis Perikles, Sardis Andreas, Leotsakou Christina   +2 more
doaj   +1 more source

Comparison of second generation antipsychotics: are there any differences in efficacy?

Annals of General Psychiatry, 2006
Papageorgiou George
doaj   +1 more source